257 related articles for article (PubMed ID: 21852545)
1. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H
Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545
[TBL] [Abstract][Full Text] [Related]
2. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
J Virol; 2019 May; 93(9):. PubMed ID: 30787156
[TBL] [Abstract][Full Text] [Related]
5. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH
Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141
[TBL] [Abstract][Full Text] [Related]
6. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
[TBL] [Abstract][Full Text] [Related]
7. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
[TBL] [Abstract][Full Text] [Related]
9. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.
Morello CS; Levinson MS; Kraynyak KA; Spector DH
J Virol; 2011 Apr; 85(7):3461-72. PubMed ID: 21270160
[TBL] [Abstract][Full Text] [Related]
10. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM
Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.
Awasthi S; Hook LM; Swaminathan G; Cairns TM; Brooks B; Smith JS; Ditto NT; Gindy ME; Bett AJ; Espeseth AS; Cohen GH; Friedman HM
Vaccine; 2019 Jun; 37(29):3770-3778. PubMed ID: 31153687
[TBL] [Abstract][Full Text] [Related]
12. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
13. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
[TBL] [Abstract][Full Text] [Related]
16. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
Bernstein DI; Farley N; Bravo FJ; Earwood J; McNeal M; Fairman J; Cardin R
Vaccine; 2010 May; 28(21):3748-53. PubMed ID: 19857450
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
[TBL] [Abstract][Full Text] [Related]
18. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.
Awasthi S; Hook LM; Shaw CE; Friedman HM
Hum Vaccin Immunother; 2017 Dec; 13(12):2785-2793. PubMed ID: 28481687
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
[TBL] [Abstract][Full Text] [Related]
20. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
